Miguel Forte
President, ISCT and CEO, Kiji Therapeutics
A member of the European Advisory Board with the Alliance for Regenerative Medicine, as well as a professor at the Faculty of Pharmacy, University of Lisbon, Miguel has been leading and championing the cell and gene sector for decades in academic, regulatory, and industry CEO roles. Heading up Kiji Therapeutics and sitting on the board of many other biotechs, including Swarm Oncology, Stembond Technologies, and mC4Tx, Miguel, a Power List veteran since 2016, returns following a successful 2024 and promising pipeline with Kiji Therapeutics.
“As technology evolves and improves, adoption will grow. Likewise, as competition increases, we will see a reduction in the cost of cell and gene products. We will progress from the smaller, orphan indications to larger patient number indications, evolving the business model from low numbers and high cost to higher numbers and lower costs.”
